Eli Sprecher

I Derm Pharma is an Israeli biotechnology company focused on developing first-in-class therapies for autoimmune inflammatory skin diseases, specifically psoriasis. The company was co-founded in 2022 by Professor Eli Sprecher, a leading expert in genetic dermatology and CEO of Tel Aviv Sourasky Medical Center, alongside Dr. Sharon Navon and Dr. Ofer Sarig. I Derm Pharma’s lead candidate is a proprietary small molecule (CPT-11) that targets a novel inflammatory pathway in the skin by up-regulating SAMD9 and down-regulating EGR1. This mechanism aims to modulate inflammation locally without the systemic immunosuppression or toxicity common in existing treatments. The company is advancing both oral and topical formulations through early-stage clinical development to provide safer alternatives to injectable biologics.